Hit enter to search or ESC to close
ERA4TB
  • The Project
  • Consortium
  • News
    • Events
    • Press
    • Newsletter
    • Video Library
  • Results
  • TB Facts
  • SharePoint
Event

ERA4TB 5th Consortium Meeting: First F2F meeting in Madrid after the pandemic

On June 20th and 21st the fifth Consortium Meeting took place in Madrid. The meeting…
Andrea Garcia
Andrea GarciaJune 22, 2022
Event

5th Consortium Meeting on 20th and 21st of June 2022 – After 2 years, ERA4TB meets again face to face in Madrid

More than 120 representatives of ERA4TB partners are meeting face to face with the occasion…
IT Synapse
IT SynapseJune 17, 2022
News

ERA4TB welcomes CIM – Sant Pau (IIB Sant Pau) as New Partner

ERA4TB announced on the 4th Consortium Meeting that CIM – Sant Pau (IIB Sant Pau)…
IT Synapse
IT SynapseFebruary 1, 2022
News

The ERA4TB Scientific Advisory Board has been set up

Dr Gilla Kaplan, Ph.D. Former Director of the Global Health Program, Tuberculosis, at the Bill…
IT Synapse
IT SynapseFebruary 1, 2022
Event

ERA4TB 4th Consortium Meeting: The Time to Make a Difference

On the 27th and 28th of January 2022, Consortium members gathered virtually for two days…
IT Synapse
IT SynapseJanuary 31, 2022
News

ERA4TB SCHEDULES THE 4TH CONSORTIUM MEETING ON 27TH AND 28TH OF JANUARY 2022

The ERA4TB 4th Consortium Meeting is taking place next 27th -28th January 2022 as a…
Inari Soininen
Inari SoininenDecember 3, 2021
Press

Advancing Clinical Research Capacity in Europe: Almari Conradie on TBAJ-587 and the ERA4TB Project [TB Alliance]

TBAJ-587-CL-001 is the first Phase 1 trial in humans conducted by TB Alliance through the…
Inari Soininen
Inari SoininenNovember 26, 2021
Event

Project Update – 3th Consortium Meeting

The third ERA4TB Consortium Meeting took place last June 9th and 10th with the participation…
Inari Soininen
Inari SoininenJune 15, 2021
Press

COVID-19 highlights urgent need to reboot global effort to end tuberculosis [Press Release – WHO]

An estimated 1.4 million fewer people received care for tuberculosis (TB) in 2020 than in…
Inari Soininen
Inari SoininenMarch 26, 2021
Event

Consortium Meeting

On January 26th and 27th the second Consortium Meeting took place online to share the…
Inari Soininen
Inari SoininenFebruary 2, 2021
1 2 Next

Recent Posts

  • ERA4TB 5th Consortium Meeting: First F2F meeting in Madrid after the pandemic
  • 5th Consortium Meeting on 20th and 21st of June 2022 – After 2 years, ERA4TB meets again face to face in Madrid
  • ERA4TB welcomes CIM – Sant Pau (IIB Sant Pau) as New Partner
  • The ERA4TB Scientific Advisory Board has been set up
  • ERA4TB 4th Consortium Meeting: The Time to Make a Difference

Categories

  • Event
  • News
  • Press

TWITTER

ERA4TB ProjectFollow

Research consortium developing new treatments for TB European Regimen Accelerator for Tuberculosis Grant Agreement no. 853989 — ERA4TB https://t.co/BXboc1TV3r

ERA4TB Project
Retweet on TwitterERA4TB Project Retweeted
8 Aug

In this interview with @NewsMedical, Head of Therapeutics Development Charles Wells discusses our current research into #tuberculosis, @WHO's new guidelines for TB care, and what inspired his career. Read more: https://bit.ly/3BJmYVt

Reply on Twitter 1556617328204341248Retweet on Twitter 15566173282043412487Like on Twitter 155661732820434124812Twitter 1556617328204341248
Retweet on TwitterERA4TB Project Retweeted
5 Aug

👩‍💻📊Towards a more sustainable use of #AMR data: @IHIEurope project @FAIRplus_eu investigated in a case study the 'FAIRification' of @AMR_Combine data #StrongerTogether in the fight against #AMR and resistant #TB: https://twitter.com/FAIRplus_eu/status/1555154114924929025?s=20&t=trfEnNpti6-oxLFNz6xa6g

#antimicrobialstewardship #DataScience

FAIRplus@FAIRplus_eu

Many antimicrobial resistance data 🧫 are hardly reusable due to lack of #interoperability. ✨ Our #FAIRplus squad developed a new application ontology that combined several existing ontologies.

🙌 Read our case study on #IMI_COMBINE to find out more: https://fairplus-project.eu/news/fairplus-combine-case-study

Reply on Twitter 1555487340344348673Retweet on Twitter 15554873403443486733Like on Twitter 15554873403443486733Twitter 1555487340344348673
Retweet on TwitterERA4TB Project Retweeted
4 Aug

Though tremendous progress against TB has been made in the last two decades, the world needs new interventions to prevent and treat this disease. At the Gates MRI, we're supporting and developing multiple vaccines and therapeutics urgently needed to improve outcomes and #endTB. https://twitter.com/TBAlliance/status/1546529505317212163

TB Alliance@TBAlliance

In the past 200 years, #tuberculosis has claimed over a billion lives. Now, TB kills more than 4,100 people every day. Learn more about how we can work together to fight one of the world's oldest diseases and finally #endTB: https://www.tballiance.org/

Reply on Twitter 1555171277937278977Retweet on Twitter 15551712779372789771Like on Twitter 15551712779372789773Twitter 1555171277937278977
Retweet on TwitterERA4TB Project Retweeted
4 Aug

Please RT: Postdoctoral position available in mycobacteriology and single-cell technologies in the Microbial Individuality and Infection Lab at the Institut Pasteur in Paris. Please see details below.

Reply on Twitter 1555245810627010561Retweet on Twitter 1555245810627010561174Like on Twitter 1555245810627010561142Twitter 1555245810627010561
Retweet on TwitterERA4TB Project Retweeted
3 Aug

"The biopharmaceutical industry agrees that we must use antibiotics judiciously, but those efforts are useless without a pipeline of novel antimicrobial treatments." #AMR https://www.washingtonpost.com/opinions/2022/07/29/superbugs-require-super-solutions/

Reply on Twitter 1554848775453163525Retweet on Twitter 15548487754531635257Like on Twitter 155484877545316352522Twitter 1554848775453163525
Load More...
Acknowledgement:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989.
The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non profit organisation, Bill & Melinda Gates Foundation and University of Dundee.
Contact:
info@era4tb.org
The Project
  • About
  • Objectives
  • Ambitions
  • Structure
Consortium
  • Partners
  • Advisors
News
  • News
  • Newsletter
  • Events
  • Media
Result
  • Publications
  • Deliverables

© 2022 ERA4TB. About IMI - Disclaimer - Cookies Policy - Legal Notice

  • The Project
  • Consortium
  • News
    • Events
    • Press
    • Newsletter
    • Video Library
  • Results
  • TB Facts
  • SharePoint
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookies PolicyACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.